thiazolyl blue has been researched along with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JH; Chang, YL; Cheng, FC; Guh, JH; Kuo, SC; Lee, FY; Pan, SL; Peng, CY; Teng, CM; Wang, SW | 1 |
1 other study(ies) available for thiazolyl blue and 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
| Article | Year |
|---|---|
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Blotting, Western; Cell Movement; Cell Proliferation; Endothelial Cells; Endothelium, Vascular; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Guanylate Cyclase; Humans; Indazoles; Longevity; Microtubules; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Protein Kinase C; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine; Vascular Endothelial Growth Factor A | 2005 |